ChAdOx1 Puns

Study (n=9755) finds no evidence for change in fertility (n=93) or miscarriage (n=107) following ChAdOx1 nCoV-19 (AZD1222) vaccination

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial thelancet.com/journals/la…

Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil thelancet.com/journals/la…

The Lancet* confirms that the use of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination is an effective alternative to increase population immunity against Covid-19, including against the Delta variant

ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome science.org/doi/10.1126/s…

Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil thelancet.com/journals/la…

Study (n=9755) finds no evidence for change in fertility (n=93) or miscarriage (n=107) following ChAdOx1 nCoV-19 (AZD1222) vaccination thelancet.com/journals/la…

ChAdOx1 nCoV-19 effectiveness during an unprecedented surge in SARS COV-2 infections ejinme.com/article/S0953-…

High failure rate of ChAdOx1 in healthcare workers during Delta variant surge: A case for continued use of masks post-vaccination medrxiv.org/content/10.11…

Effectiveness of BNT162b2 and ChAdOx1 against SARS-CoV-2 household transmission - a prospective cohort study in England medrxiv.org/content/10.11…

Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study thelancet.com/journals/la…

BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant nejm.org/doi/full/10.1056…

Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial thelancet.com/journals/la…

BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant | NEJM nejm.org/doi/full/10.1056…

ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants biorxiv.org/content/10.11…

Comparative effectiveness of ChAdOx1 versus BNT162b2 COVID-19 vaccines in Health and Social Care workers in England: a cohort study using OpenSAFELY medrxiv.org/content/10.11…

Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccination nature.com/articles/s4158…

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1 thelancet.com/journals/la…

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination thelancet.com/journals/la…

Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models stm.sciencemag.org/conten…

The Safety and Immunogenicity of Concomitant Administration of COVID-19 Vaccines (ChAdOx1 or BNT162b2) with Seasonal Influenza Vaccines in Adults: A Phase IV, Multicentre Randomised Controlled Trial with Blinding (ComFluCOV) papers.ssrn.com/sol3/pape…

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study thelancet.com/journals/la…

Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, and thrombocytopenic events: whole population cohort study in 46 million adults in England medrxiv.org/content/10.11…

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) thelancet.com/journals/la…

Waning of SARS-CoV-2 antibodies targeting the Spike protein in individuals post second dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and risk of breakthrough infections: analysis of the Virus Watch community cohort. medrxiv.org/content/10.11…

Public Health England COVID-19 symptomatic effectiveness study finds two doses of BNT162b2 (Pfizer) at 93.7% (95% CI, 91.6 to 95.3) vs Alpha and 88.0% (95% CI, 85.3 to 90.1) vs Delta; ChAdOx1 (Astrazeneca) at 74.5% (95% CI, 68.4 to 79.4) vs Alpha and 67.0% (95% CI, 61.3 to 71.8) vs Delta nejm.org/doi/full/10.1056…

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1 thelancet.com/journals/la…

Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant(B.1.617.2) of SARS-CoV-2 medrxiv.org/content/10.11…

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1 thelancet.com/journals/la…

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine nejm.org/doi/full/10.1056…

Cellular Immune Responses are Preserved and May Contribute to Chadox1 ChAdOx1 nCoV-19 Vaccine Effectiveness Against Infection Due to SARS-CoV-2 B·1·617·2 Delta Variant Despite Reduced Virus Neutralisation papers.ssrn.com/sol3/pape…

Spike-Antibody Waning After Second Dose of BNT162b2 or ChAdOx1 thelancet.com/journals/la…

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK marlin-prod.literatumonli…

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial thelancet.com/journals/la…

Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity medrxiv.org/content/10.11…

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant nejm.org/doi/full/10.1056…

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study bmj.com/content/373/bmj.n…

SARS-CoV-2 anti-spike IgG antibody responses after second dose of ChAdOx1 or BNT162b2 in the UK general population medrxiv.org/content/10.11…

Antibody Responses After a Single Dose of ChAdOx1 nCoV-19 Vaccine in Healthcare Workers Previously Infected with SARS-CoV-2 medrxiv.org/content/10.11…

ChAdOx1 nCov-19 provides minimal protection against mild-moderate COVID-19 infection from B.1.351 coronavirus variant in young South African adults ox.ac.uk/news/2021-02-07-…

Heterologous ChAdOx1-nCoV19–BNT162b2 vaccination provides superior immunogenicity against COVID-19 thelancet.com/journals/la…

Heterologous prime-boost vaccination with ChAdOx1 (AstraZeneca) and BNT162b2 mRNA (Pfizer) medrxiv.org/content/10.11…

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination nature.com/articles/s4159…

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination nature.com/articles/s4159…

Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination nejm.org/doi/full/10.1056…